Actively Recruiting
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-04-20
150
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
T
The University of Texas Health Science Center at San Antonio
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are creating a living biobank of patient-derived organoids (PDOs) from people with lung cancer at all clinical stages, from Stage I to IV. The aim is to collect tumor specimens from at least 50 patients to study lung tumor types, staging, and characteristics. This observational study will not provide any specific treatment but will store PDOs for future research to better understand lung cancer biology and treatment responses. This study involves collecting tumor tissue during lung tumor resection surgery. The collected tumor specimens will be used to establish and culture PDOs, which are then biobanked for later experiments. In addition, circulating tumor cells (CTCs) and lung organoids will be cultured and analyzed using various laboratory techniques such as histology, immunohistochemistry, atomic force measurements, and proteomic profiling to study tumor features and oncogenic pathways. Participants will provide demographic information and complete surveys about their environmental and occupational exposures as well as smoking and alcohol history. Data on treatment and survival history will also be collected at scheduled intervals. The main outcome is to develop and characterize the PDO biobank and explore how well PDOs reflect responses to chemotherapy and targeted agents observed clinically. The study will monitor correlations between PDOs and CTCs over a 10-year period. No investigational treatments are given, and participant involvement centers on tissue donation and survey completion.
CONDITIONS
Brief Title
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
- Diagnosis of lung cancer or lung mass or lymphadenopathy that will either receive systemic treatment or tumor resection as part of standard of care
- Any clinical stage of lung cancer
- Adult patients 6518 years of age
- Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history
You will not qualify if you...
- At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo lung tumor resection to collect tumor specimens for organoid creation.
1 visit (in-person)
Duration - Up to 10 years
Participants are observed while their tumor specimens are used to establish and characterize patient-derived organoids and circulating tumor cells.
Follow-up visits as part of routine care; frequency depends on individual patient care
Trial Site Locations
Total: 1 location
1
UT Health San Antonio, M.D. Anderson Cancer Center
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
J
Josephine Taverna, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here